title: [Hylacombun in inflammatory bowel diseases].
abstract: Treatment of non-specific bowel inflammation (NBI) particularly of Crohn's disease (MD) and ulcerative colitis is very complicated, especially because of the fact, that in spite of atrial successful findings, the etiology of both main diseases of this group remain unknown. Nevertheless, manifestations, particularly in MC vary, often unexpectedly and surprisingly. Different medical teams elaborate therapeutic schedules, but none of them has been accepted world-wide. As it is still possible to state that NBI is untreatable by drug therapy, even the surgical removal of the affected part of the bowel does not protect against the relapse, it may indicate that no therapeutical approaches are sufficient at present. Using drug therapy, the biochemical chain of numerous inflammatory mediators is being tried to be disrupted. Despite the advances achieved, there are still many difficulties related to drug therapy. It is necessary to take into account the fact that the lack of knowledge in causative therapy and failure, poor response to initial therapy lead to the use of more new drugs. Therefore a careful consideration of every used or recommended drug is necessary. The principle of using Hylacombun (Merckle) in therapy was not applied due to the presumption of influencing the disease fundamentally, but due to an effort to reduce some symptoms of the disease, which deteriorate the life quality of patients. Data given by patients in questionnaires as well as biochemical and haematological parameters were evaluated statistically. Besides the commonly used Student t-test, we used Box and Whisker plots, linear trend analysis and the method of 9 aggregation numbers to follow both dynamics of the disease and drug effect. Laboratory, as well as the questionnaire data were equilibrated and graphically illustrated by the spline method. We found out that Hylacombun was effective in all patients. Subjective improvement was shown after 10 days of therapy, stabile improvement after 2 months. (Tab. 3, Fig. 7, Ref. 9.).
authors.affiliation: Výskumný ústav výzivy v Bratislave a Mediconsult v Nitre, Bratislava, Slovakia.
authors.forename: M
authors.initials: M
authors.lastname: Príkazska
authors.forename: M
authors.initials: M
authors.lastname: Letkovicová
mesh_terms: D000328:Adult; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006912:Hydroxyquinolines / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010194:Pancreatin / Q000627:therapeutic use*; D010208:Papaverine / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D006912:Hydroxyquinolines; C010197:1-((3,4-diethoxyphenyl)methyl)-6, 5,7-dichloro-8-quinolinol, 7-diethoxyisoquinoline hydrochloride, pancreatin drug combination; D010194:Pancreatin; D010208:Papaverine
vernacular_title: Hylacombun pri zápalových chorobách criev.